VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 335 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2017. The put-call ratio across all filers is 1.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $697,000 | +45.8% | 30,000 | 0.0% | 0.00% | +33.3% |
| Q1 2018 | $478,000 | -23.3% | 30,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $623,000 | +44.9% | 30,000 | 0.0% | 0.00% | +50.0% |
| Q3 2017 | $430,000 | -17.1% | 30,000 | 0.0% | 0.00% | -33.3% |
| Q2 2017 | $519,000 | +56.8% | 30,000 | 0.0% | 0.00% | +50.0% |
| Q1 2017 | $331,000 | +2106.7% | 30,000 | +2900.0% | 0.00% | – |
| Q4 2016 | $15,000 | -97.2% | 1,000 | -95.1% | 0.00% | -100.0% |
| Q1 2016 | $537,000 | -68.9% | 20,404 | +20.1% | 0.00% | -66.7% |
| Q4 2015 | $1,727,000 | -16.8% | 16,988 | +46.0% | 0.01% | -18.2% |
| Q3 2015 | $2,075,000 | -11.2% | 11,632 | +10.5% | 0.01% | 0.0% |
| Q2 2015 | $2,338,000 | +11.8% | 10,526 | 0.0% | 0.01% | +22.2% |
| Q1 2015 | $2,091,000 | +6236.4% | 10,526 | +3948.5% | 0.01% | – |
| Q2 2014 | $33,000 | -2.9% | 260 | 0.0% | 0.00% | – |
| Q1 2014 | $34,000 | – | 260 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |